These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 18808404)

  • 61. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring.
    Knechtle SJ; Pascual J; Bloom DD; Torrealba JR; Jankowska-Gan E; Burlingham WJ; Kwun J; Colvin RB; Seyfert-Margolis V; Bourcier K; Sollinger HW
    Am J Transplant; 2009 May; 9(5):1087-98. PubMed ID: 19344431
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Protocol biopsies in pediatric renal transplant recipients on cyclosporine versus tacrolimus-based immunosuppression.
    Aoun B; Decramer S; Vitkevic R; Wannous H; Bandin F; Azema C; Callard P; Brocheriou I; Ulinski T
    Pediatr Nephrol; 2013 Mar; 28(3):493-8. PubMed ID: 23111894
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Rituximab induction therapy in highly sensitized kidney transplant recipients.
    Yin H; Wan H; Hu XP; Li XB; Wang W; Liu H; Ren L; Zhang XD
    Chin Med J (Engl); 2011 Jul; 124(13):1928-32. PubMed ID: 22088448
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Significance of intragraft CD138+ lymphocytes and p-S6RP in pediatric kidney transplant biopsies.
    Tsai EW; Wallace WD; Gjertson DW; Reed EF; Ettenger RB
    Transplantation; 2010 Oct; 90(8):875-81. PubMed ID: 20736897
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pinpoint targeted immunosuppression: anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy.
    Saito K; Nakagawa Y; Suwa M; Kumagai N; Tanikawa T; Nishiyama T; Ueno M; Gejyo F; Nishi S; Takahashi K
    Xenotransplantation; 2006 Mar; 13(2):111-7. PubMed ID: 16623803
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Phenotypic evaluation of B-cell subsets after rituximab for treatment of acute renal allograft rejection in pediatric recipients.
    Zarkhin V; Lovelace PA; Li L; Hsieh SC; Sarwal MM
    Transplantation; 2011 May; 91(9):1010-8. PubMed ID: 21403590
    [TBL] [Abstract][Full Text] [Related]  

  • 67. High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis.
    Tanriover B; Wright SE; Foster SV; Roush KS; Castillo-Lugo JA; Fa K; Levy FL; Mejia A
    Transplant Proc; 2008 Dec; 40(10):3393-6. PubMed ID: 19100397
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The efficacy and safety of high-dose mizoribine in ABO-incompatible kidney transplantation using anti-CD20 and anti-CD25 antibody without splenectomy treatment.
    Yoshimura N; Ushigome H; Matsuyama M; Nobori S; Suzuki T; Sakai K; Okajima H; Okamoto M
    Transplant Proc; 2012 Jan; 44(1):140-3. PubMed ID: 22310599
    [TBL] [Abstract][Full Text] [Related]  

  • 69. CD20-positive infiltrates in renal allograft biopsies with acute cellular rejection are not associated with worse graft survival.
    Bagnasco SM; Tsai W; Rahman MH; Kraus ES; Barisoni L; Vega R; Racusen LC; Haas M; Mohammed BS; Zachary AA; Montgomery RA
    Am J Transplant; 2007 Aug; 7(8):1968-73. PubMed ID: 17617861
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Influence of preoperative anti-HLA antibodies on short- and long-term graft survival in recipients with or without rituximab treatment.
    Ishida H; Furusawa M; Shimizu T; Nozaki T; Tanabe K
    Transpl Int; 2014 Apr; 27(4):371-82. PubMed ID: 24438437
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The fate of C4d positive kidney allografts lacking histological signs of acute rejection.
    Dickenmann M; Steiger J; Descoeudres B; Mihatsch M; Nickeleit V
    Clin Nephrol; 2006 Mar; 65(3):173-9. PubMed ID: 16550748
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clearance of Intra-graft Donor Specific Anti-HLA Antibodies in the Early Stage of Antibody-Mediated Rejection Following Rituximab and Apheresis Therapy in Renal Transplantation.
    Nakamura T; Yoshimura N; Akioka K; Shirouzu T; Kawai S; Imanishi Y; Matsuyama T; Harada S; Nobori S; Ushigome H
    Transplant Proc; 2019 Jun; 51(5):1365-1370. PubMed ID: 31056246
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period.
    Kohei N; Hirai T; Omoto K; Ishida H; Tanabe K
    Am J Transplant; 2012 Feb; 12(2):469-76. PubMed ID: 22054413
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Antibody-mediated rejection in hand transplantation.
    Weissenbacher A; Hautz T; Zelger B; Zelger BG; Mayr V; Brandacher G; Pratschke J; Schneeberger S
    Transpl Int; 2014 Feb; 27(2):e13-7. PubMed ID: 24266875
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.
    Waiser J; Budde K; Schütz M; Liefeldt L; Rudolph B; Schönemann C; Neumayer HH; Lachmann N
    Nephrol Dial Transplant; 2012 Mar; 27(3):1246-51. PubMed ID: 21852274
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Failure of anti-CD20 monoclonal antibody therapy to prevent antibody-mediated rejection in three crossmatch-positive renal transplant recipients.
    Matignon M; Tagnaouti M; Audard V; Dahan K; Lang P; Grimbert P
    Transplant Proc; 2007 Oct; 39(8):2565-7. PubMed ID: 17954175
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Association between response to rituximab and antibody-mediated rejection in ABO-incompatible living kidney transplantation.
    Maenosono R; Unagami K; Kakuta Y; Furusawa M; Okumi M; Azuma H; Ishida H; Tanabe K
    Int J Urol; 2019 Dec; 26(12):1114-1120. PubMed ID: 31522467
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G; Walsh G; Deshpande P; Koffman G
    Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Indicators of treatment responsiveness to rituximab and plasmapheresis in antibody-mediated rejection after kidney transplantation.
    Immenschuh S; Zilian E; Dämmrich ME; Schwarz A; Gwinner W; Becker JU; Blume CA
    Transplantation; 2015 Jan; 99(1):56-62. PubMed ID: 25121474
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinicopathologic analysis of acute vascular rejection cases after renal transplantation.
    Shimizu T; Tanabe T; Omoto K; Ishida H; Tanabe K
    Transplant Proc; 2012 Jan; 44(1):230-5. PubMed ID: 22310621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.